The muscarinic agonist xanomeline increases monoamine release and immediate early gene expression in the rat prefrontal cortex

Biological Psychiatry

Volumn 49, Issue 8, 2001, Pages 716-725

  Perry, Kenneth W ^a   Nisenbaum, Laura K ^a   George, Carolyn A ^a   Shannon, Harlan E ^a   Felder, Christian C ^a   Bymaster, Frank P ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Antipsychotic; Fos; Gene expression; Muscarinic agonist; Neurotransmitter release; Schizophrenia; Xanomeline

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 5 HYDROXYINDOLEACETIC ACID; CLOZAPINE; COMPLEMENTARY DNA; DOPAMINE; MESSENGER RNA; MONOAMINE; MUSCARINIC AGENT; NORADRENALIN; OLANZAPINE; PROTEIN C FOS; SEROTONIN; XANOMELINE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BRAIN REGION; CELL LEVEL; CONTROLLED STUDY; CORPUS STRIATUM; DNA TEMPLATE; DRUG EFFECT; GENE EXPRESSION; HISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MICRODIALYSIS; MONOAMINE RELEASE; NONHUMAN; NUCLEOTIDE SEQUENCE; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT;

EID: 0035871580     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(00)01017-9     Document Type: Article

References (63)

1. Drug-induced changes of dopamine turnover in striatum and limbic system in rat
2. The prefrontal cortex in schizophrenia and other neuropsychiatric diseases: In vivo physiological correlates of cognitive deficits
3. The effects of xanomeline, an M1-selective muscarinic agonist, on cognitive and behavioral symptoms in Alzheimer's disease
4. Comparative behavioral and neurochemical activities of cholinergic antagonists in rats
5. 1-adrenergic receptors in vitro
6. In vitro and in vivo biochemistry of olanzapine: A novel, atypical antipsychotic drug
7. Unexpected antipsychotic-like activity with the muscarinic agonist receptor ligand (5R,6R)6-(3-propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1]octane
8. Potential role of muscarinic receptors in schizophrenia
9. Xanomeline: A selective muscarinic agonist for the treatment of Alzheimer's disease
10. Neurochemical effects of the M1 agonist xanomeline (LY246708/NNC11-0232)
11. Typical and atypical neuroleptics: Differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons
12. Physostigmine ameliorates the delusions of Alzheimer's disease
13. Effect of M1- and M2-muscarinic drugs on striatal dopamine release and metabolism: An in vivo microdialysis study comparing normal and 6-hydroxydopamine-lesioned rats
14. Regionally specific effects of atypical antipsychotic drugs on striatal fos expression: The nucleus accumbens shell as a locus of antipsychotic action
15. Mechanisms of action of atypical antipsychotic drugs. Implications for novel therapeutic strategies for schizophrenia
16. Modulatory functions of neurotransmitters in the striatum: ACh/dopamine/NMDA interactions
17. 3 receptors
18. 11C]Butylthio-TZTP in monkey and man
19. Effect of typical and atypical neuroleptics on fos protein expression in the rat forebrain
20. The prefrontal landscape: Implications of functional architecture for understanding human mentation and the central executive
21. Pronounced pharmacological deficits in M2 muscarinic acetylcholine receptor knockout mice
22. Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M4 muscarinic acetylcholine receptor mice
23. Cholinergic therapy of behavioral disturbances in Alzheimer's disease
24. Activation of midbrain presumed dopaminergic neurones by muscarinic cholinergic: An in vivo electrophysiological study
25. 1 muscarinic antagonists interact with σ recognition sites
26. Muscarinic receptor-mediated induction of Fos protein in rat brain
27. Activation of pirenzepine-sensitive muscarinic receptors induces a specific pattern of immediate-early gene expression in rat brain neurons
28. Effect of tacrine on behavior in Alzheimer's disease: An open label study
29. Effects of acute and repeated administration of antidepressant drugs on extracellular levels of 5-hydroxytryptamine measured in vivo
30. 1A receptor agonist, inhibits amphetamine-induced serotonin and dopamine release in rat medial prefrontal cortex
31. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens
32. Immunological localization of m1-m5 muscarinic acetylcholine receptors in peripheral tissues and brain
33. Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum
34. Organization of the catecholamines neurons projecting to the frontal cortex in the rat
35. Dopamine and norepinephrine-containing neuron systems: Their anatomy in rat brain
36. On the presence in the cerebral cortex of muscarinic receptor subtypes which differ in neuronal localization, function and pharmacological properties
37. Neurotransmitter actions in the thalamus and cerebral cortex and their role in neuromodulation of thalamocortical activity
38. Acetylcholinesterase-rich neurons of the human cerebral cortex: Cytoarchitectonic and ontogenetic patterns of distribution
39. Differential cholinergic innervation within functional subdivisions of the human cerebral cortex: A choline acetyltransferase study
40. Preferential activation of cortical dopamine neurotransmission by clozapine: Functional significance
41. Effect of oxotremorine on homovanillic acid concentration in the striatum of the rat
42. Acetylcholine and hallucinations: Disease-related compared to drug-induced alterations in human consciousness
43. The muscarinic agonist xanomeline has antipsychotic-like activity in animals and in man
44. Effect of serotonin and dopamine concentrations in microdialysis fluid from rat striatum
45. Effects of olanzapine on regional c-Fos expression in rat forebrain
46. Induction patterns of fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity
47. Muscarinic agonists with antipsychotic-like activity: Relationships of 1,2,5-thiadiazole analogues with functional dopamine antagonist document
48. 1-dopamine receptors in working memory: Local injections of dopamine antagonists into the prefrontal cortex of rhesus monkeys performing an oculomotor delayed-response task
49. Olanzapine-induced fos expression in the rat forebrain: Cross-tolerance with haloperidol and clozapine
50. Antipsychotic-like pharmacologic profile of the muscarinic agonist BuTAC
51. Xanomeline: A novel muscarinic receptor agonist with functional selectivity for M1 receptors
52. Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance response in rats
53. Muscarinic modulation of striatal dopamine, glutamate, and GABA release as measured with in vivo microdialysis
54. Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons
55. Topography of serotonin neurons in the dorsal raphe nucleus that send axon collaterals to the rat prefrontal cortex and nucleus accumbens
56. BIMG 80, a novel potential antipsychotic drug: Evidence for multireceptor actions and prefrontal release of dopamine in prefrontal cortex
57. Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors
58. Expression of muscarinic acetylcholine and dopamine receptor mRNAs in rat basal ganglia
59. Sequence and significance of dopamine metabolism in the rat brain
60. Do neurotransmitters sampled by brain microdialysis reflect functional release?
61. Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons
62. Differential effects of M1 and M2-muscarinic drugs on striatal dopamine release and metabolism in freely moving rats